EVA is registered trademark of Stern Stewart.
Economic value added or economic profit is the difference between revenues and costs,where costs include not only expenses, but also cost of capital.
Paying user area
Try for free
HCA Healthcare Inc. pages available for free this week:
- Income Statement
- Statement of Comprehensive Income
- Cash Flow Statement
- Common-Size Balance Sheet: Assets
- Analysis of Solvency Ratios
- Common Stock Valuation Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Enterprise Value to FCFF (EV/FCFF)
- Return on Equity (ROE) since 2011
- Price to Book Value (P/BV) since 2011
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to HCA Healthcare Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Economic Profit
| 12 months ended: | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | |
|---|---|---|---|---|---|---|
| Net operating profit after taxes (NOPAT)1 | ||||||
| Cost of capital2 | ||||||
| Invested capital3 | ||||||
| Economic profit4 | ||||||
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 NOPAT. See details »
2 Cost of capital. See details »
3 Invested capital. See details »
4 2021 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= – × =
The economic profit performance between 2017 and 2021 exhibits significant volatility, characterized by an initial phase of growth, a sharp decline into negative territory, and a subsequent substantial recovery.
- Net Operating Profit After Taxes (NOPAT)
- A general upward trajectory is observed, with NOPAT rising from US$ 4,332 million in 2017 to US$ 9,050 million in 2021. While a slight contraction occurred in 2020, the 2021 results indicate a sharp acceleration in operational profitability, reflecting a substantial increase in earnings power relative to the preceding years.
- Invested Capital and Cost of Capital
- Invested capital grew consistently throughout the period, increasing from US$ 27,635 million to US$ 36,837 million. Concurrently, the cost of capital trended upward, rising from 14.29% in 2017 to 17.78% in 2021. This simultaneous expansion of the capital base and the increase in the hurdle rate intensified the requirement for higher operating returns to sustain positive value creation.
- Economic Profit and Value Creation
- Economic profit remained positive from 2017 to 2019, reaching US$ 889 million in 2018. A transition to value destruction occurred in 2020, where economic profit fell to negative US$ 345 million. This deficit was a result of a dip in NOPAT coinciding with a higher cost of capital applied to an expanded capital base. The trend reversed sharply in 2021, with economic profit peaking at US$ 2,499 million, indicating that NOPAT growth significantly outpaced the increase in the cost of capital and invested assets.
Net Operating Profit after Taxes (NOPAT)
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 Elimination of deferred tax expense. See details »
2 Addition of increase (decrease) in equity equivalents to net income attributable to HCA Healthcare, Inc..
3 2021 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =
4 2021 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =
5 Addition of after taxes interest expense to net income attributable to HCA Healthcare, Inc..
- Net Income Attributable to HCA Healthcare, Inc.
- The net income shows a general upward trend over the analyzed period. Starting at 2,216 million US dollars in 2017, the figure increased significantly to 3,787 million in 2018, representing strong growth. There was a slight decline in 2019 to 3,505 million, followed by a moderate recovery in 2020 to 3,754 million. Notably, the net income surged markedly in 2021, reaching 6,956 million US dollars, indicating a substantial increase and a possible improvement in operational efficiency or market conditions.
- Net Operating Profit After Taxes (NOPAT)
- The NOPAT values also exhibit a consistent upward trajectory with minor fluctuations. Beginning at 4,332 million US dollars in 2017, it rose steadily to 5,865 million in 2018 and slightly higher to 5,941 million in 2019. A small decrease occurred in 2020, with NOPAT declining to 5,607 million. However, a significant increase is evident in 2021, with NOPAT rising sharply to 9,050 million US dollars. This substantial growth in 2021 may reflect enhanced operational performance or effective cost management, contributing to improved profitability after taxes.
Cash Operating Taxes
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
- Provision for Income Taxes
- The provision for income taxes exhibited a fluctuating pattern over the five-year period. Initially, there was a decline from 1,638 million US dollars in 2017 to 946 million in 2018. This was followed by an increase in 2019 to 1,099 million. In 2020, the provision slightly decreased to 1,043 million, but surged significantly in 2021 to 2,112 million US dollars, representing the highest level in the observed timeframe.
- Cash Operating Taxes
- Cash operating taxes showed a general upward trend despite some variability. The amount decreased from 1,829 million US dollars in 2017 to 1,319 million in 2018, then marginally declined again to 1,225 million in 2019. However, there was a notable increase in 2020 to 1,505 million, followed by a substantial rise in 2021 to 2,444 million US dollars, reaching the peak value for the period under review.
- Comparative Analysis
- Both the provision for income taxes and cash operating taxes demonstrated significant increases in 2021, more than doubling their respective lows in 2018 and 2019. The divergence in trends between 2017 and 2018 indicates an initial reduction phase before a strong upward movement. The cash operating taxes consistently remained higher than the provision for income taxes each year, suggesting a potential difference in the timing or recognition of tax expenses compared to actual tax payments.
Invested Capital
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 Addition of capitalized operating leases.
2 Elimination of deferred taxes from assets and liabilities. See details »
3 Addition of equity equivalents to stockholders’ equity (deficit) attributable to HCA Healthcare, Inc..
4 Removal of accumulated other comprehensive income.
5 Subtraction of construction in progress.
- Total reported debt & leases
-
This liability metric showed a generally stable pattern throughout the observed periods, fluctuating slightly but remaining within the range of approximately US$33 billion to US$37 billion. Specifically, the value decreased from US$34.8 billion in 2017 to US$33.1 billion in 2020, followed by an increase to US$36.7 billion in 2021. This trend suggests a degree of active debt management, with a reduction during the 2018-2020 period and an increase in the most recent year.
- Stockholders’ equity (deficit) attributable to HCA Healthcare, Inc.
-
The equity position exhibited a significant improvement from a negative value of US$6.8 billion in 2017 to nearly break-even at US$572 million in 2020, indicating a substantial repair of shareholders’ equity over this four-year span. However, in 2021, there was a reversal back to a negative equity balance of US$933 million, though this deficit was still less severe than the initial figures at the beginning of the period. This reflects volatility in retained earnings or other components influencing equity, as well as possible impacts of operational or non-operational factors on equity structure.
- Invested capital
-
A steady and continuous increase in invested capital is evident across the five-year timeframe, rising from US$27.6 billion in 2017 to US$36.8 billion in 2021. This indicates ongoing investment activity and capital deployment in the business, suggesting expansion or renewal efforts. The upward trend is consistent year-over-year without any contractions or plateaus, signaling sustained capital growth.
Cost of Capital
HCA Healthcare Inc., cost of capital calculations
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Long-term debt3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2021-12-31).
1 US$ in millions
2 Equity. See details »
3 Long-term debt. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Long-term debt3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2020-12-31).
1 US$ in millions
2 Equity. See details »
3 Long-term debt. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Long-term debt3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2019-12-31).
1 US$ in millions
2 Equity. See details »
3 Long-term debt. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Long-term debt3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2018-12-31).
1 US$ in millions
2 Equity. See details »
3 Long-term debt. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Long-term debt3 | ÷ | = | × | × (1 – 35.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 35.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2017-12-31).
1 US$ in millions
2 Equity. See details »
3 Long-term debt. See details »
4 Operating lease liability. See details »
Economic Spread Ratio
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Economic profit1 | ||||||
| Invested capital2 | ||||||
| Performance Ratio | ||||||
| Economic spread ratio3 | ||||||
| Benchmarks | ||||||
| Economic Spread Ratio, Competitors4 | ||||||
| Abbott Laboratories | ||||||
| Elevance Health Inc. | ||||||
| Intuitive Surgical Inc. | ||||||
| Medtronic PLC | ||||||
| UnitedHealth Group Inc. | ||||||
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 Economic profit. See details »
2 Invested capital. See details »
3 2021 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =
4 Click competitor name to see calculations.
The financial performance between 2017 and 2021 is characterized by a consistent expansion of the capital base paired with significant volatility in economic value creation. While invested capital grew steadily over the five-year period, economic profit and the resulting spread ratio experienced substantial fluctuations, culminating in a sharp recovery in the final year of the period.
- Invested Capital Trends
- A sustained upward trajectory in invested capital is observed, increasing from 27,635 million US dollars in 2017 to 36,837 million US dollars in 2021. This indicates a continuous growth in the total resources deployed within the organization to generate returns.
- Economic Profit Analysis
- Economic profit demonstrated significant instability over the analyzed period. After an initial increase from 382 million US dollars in 2017 to 889 million US dollars in 2018, a downward trend followed, with profit falling to 513 million US dollars in 2019 and contracting to negative 345 million US dollars in 2020. A substantial rebound occurred in 2021, with economic profit reaching a period high of 2,499 million US dollars.
- Economic Spread Ratio Interpretation
- The economic spread ratio mirrored the fluctuations in economic profit, peaking at 2.99% in 2018 before declining. In 2020, the ratio fell to -1.00%, signifying that the return on invested capital was lower than the cost of capital, resulting in a destruction of economic value. This trend reversed aggressively in 2021, as the spread ratio climbed to 6.78%, indicating a significant expansion in the efficiency of value creation relative to the invested capital base.
Economic Profit Margin
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Economic profit1 | ||||||
| Revenues | ||||||
| Performance Ratio | ||||||
| Economic profit margin2 | ||||||
| Benchmarks | ||||||
| Economic Profit Margin, Competitors3 | ||||||
| Abbott Laboratories | ||||||
| Elevance Health Inc. | ||||||
| Intuitive Surgical Inc. | ||||||
| Medtronic PLC | ||||||
| UnitedHealth Group Inc. | ||||||
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 Economic profit. See details »
2 2021 Calculation
Economic profit margin = 100 × Economic profit ÷ Revenues
= 100 × ÷ =
3 Click competitor name to see calculations.
The financial performance from 2017 to 2021 is characterized by consistent top-line growth juxtaposed with significant volatility in economic profit and the resulting economic profit margin. While revenues expanded steadily throughout the period, the capacity to generate economic value above the cost of capital fluctuated, experiencing a notable contraction in 2020 followed by a substantial recovery in 2021.
- Revenue Trajectory
- Revenues exhibited a consistent upward trend, increasing from US$ 43,614 million in 2017 to US$ 58,752 million by the end of 2021. Growth was steady through 2019, experienced a marginal stabilization in 2020, and concluded with a sharp acceleration in 2021.
- Economic Profit Volatility
- Economic profit demonstrated significant fluctuations. After rising from US$ 382 million in 2017 to US$ 889 million in 2018, the figure declined in 2019 and shifted to a deficit of US$ 345 million in 2020. A substantial reversal occurred in 2021, with economic profit surging to US$ 2,499 million, representing the peak value within the analyzed timeframe.
- Economic Profit Margin Trends
- The economic profit margin mirrored the volatility of the absolute economic profit. The margin expanded from 0.88% in 2017 to 1.90% in 2018, before contracting to 1.00% in 2019 and falling to -0.67% in 2020. The period concluded with a significant expansion in value-creation efficiency, as the margin reached 4.25% in 2021, indicating that the increase in economic profit far outpaced the growth in revenues during the final year.